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Preventing Diabetes in American
Indian Communities
D iabetes incidence can be reduced bylifestyle interventions aimed atweight loss, diet change, and in-
creased physical activity, according to
several randomized clinical trials (RCTs)
(1–5). Similarly, diabetes incidence rates
were reduced in RCTs of metformin, aca-
rbose, troglitazone, rosiglitazone, and
pioglitazone (1,4,6–9). These RCTs en-
rolled nondiabetic adults who were at
high risk of developing type 2 diabetes
by virtue of having one of more of these
characteristics: overweight or obesity, ele-
vated fasting glucose, and impaired glu-
cose tolerance in an oral glucose tolerance
test. These lifestyle or drug interventions
reduced diabetes incidence rates substan-
tially, with risk reductions ranging from
about 25–75%. Diabetes incidence was
reduced by 58% during the 2.8-year
initial phase of the largest such lifestyle
intervention trial, the U.S. Diabetes Pre-
vention Program (DPP) (1). This occurred
among all the major race/ethnic groups in
the DPP, including American Indians.
Because of this dramatic result and
the disproportionate burden of type 2
diabetes among American Indians, the
U.S. Congress appropriated funds to im-
plement lifestyle interventions patterned on
the DPP starting in 2006 in 36 American
Indian or Alaska Native communities.
The resulting Special Diabetes Program
for Indians Diabetes Prevention (SDPI-
DP) demonstration project is described in
this issue (10). The SDPI-DP was de-
signed to deliver prevention services
to a population in need, rather than as
another RCT, because RCTs had already
shown the efficacy of lifestyle interven-
tion to prevent or delay diabetes in high
risk persons. Furthermore, the segments
of the U.S. population most affected by
type 2 diabetes, especially American In-
dians who have contributed so much to
diabetes research (11), deserve to benefit
from the results of diabetes research.
It is difficult to quantify the benefits of
the SDPI-DP and similar programs that
are not RCTs and therefore have no built-
in evaluation mechanism. Evaluation,
therefore, must rely on historical controls
or comparisons with similar programs. Un-
like most other implementation programs,
the SDPI-DP evaluated diabetes inci-
dence as well as weight change. As in
the RCTs, diabetes incidence was ascer-
tained by periodic glucose tolerance
testing of all participants who remained
under follow-up. Comparable historical
data from the same communities are not
available.
The authors compared their diabetes
incidence rate (4 per 100 person-years)
with the placebo group rate of 11 per 100
person-years and the lifestyle group rate
of 4.8 per 100 person-years in the DPP.
This comparison is difficult because eli-
gibility criteria for the SDPI-DP were
much broader than for the DPP, and
thus the SDPI-DP participants were prob-
ably at much lower risk of diabetes. For
example, DPP eligibility required eleva-
tions of both fasting and postload plasma
glucose, whereas SDPI-DP required only
one value to be elevated, which conveys a
much lower risk of diabetes (5,12). Mean
baseline 2-h glucose was 164 mg/dL (9.1
mmol/L) in the DPP (1) and 159 mg/dL
(8.8 mmol/L) in the Finnish Diabetes
Prevention Study (3), but only 123 mg/dL
(6.8 mmol/L) in SDPI-DP—substantially
below the lower limit defining impaired
glucose tolerance (7.8 mmol/L). Further-
more, it is not known what other meta-
bolic or behavioral characteristics differed
between SDPI-DP participants and those
enrolled in RCTs. The most important dif-
ference may have been the high drop-out
rate in the SDPI-DP (only 33% completed
the 3-year assessment). By comparison,
92%ofDPP participants completed a study
visit within 5 months of the end of the 2.8-
year follow-up (1).Weight loss in behavioral
treatment programs is positively corre-
lated with attendance at treatment ses-
sions (13,14), suggesting that those los-
ing less weight are less likely to complete
follow-up. Similarly, participants who
develop clinically diagnosed diabetes
may lose interest in a prevention program
and not follow-up for glucose testing in
the program (i.e., data are probably not
missing at random). Therefore, estimated
diabetes incidence might have been
much higher in the SDPI-DP if it had
been possible to assess diabetes incidence
in all enrolled subjects (15).
Community implementation is very
different from testing an intervention in
an RCT, where participants are often
highly motivated and resources are suffi-
cient to provide interventions and retain
participants. It is, therefore, informative
to compare the SDPI-DP with other
implementation programs evaluated using
largely non-RCT methods. One recent
systematic review summarized the 12-
month weight loss effectiveness of 28
previously published implementation
programs (16). Like the SDPI-DP, these
prior efforts were designed to implement
key elements of the DPP, which included
targeting high-risk adults; goal setting
and self-monitoring of dietary change,
physical activity, and modest weight
loss; and providing supportive account-
ability (typically via a lifestyle coach) to
avoid pitfalls and solve problems leading
to weight regain (17). However, the 28
previously published implementation
programs differed greatly in participant
selection, numbers of intervention ses-
sions offered, inclusion of a control
group, and how missing data were ana-
lyzed. Compared with SDPI-DP, partici-
pants in these programs were typically
older (mean age 55.1 vs. 46.6 years in
SDPI-DP) and more likely non-Hispanic
white (70.9%). Similar to SDPI-DP, prior
studies enrolled obese participants (mean
BMI 34.0 kg/m2 vs. 35.8 kg/m2 in SDPI-
DP) and women (69.9% vs. 74.5% in
SDPI-DP). Across all these programs,
mean weight change after 12 months
among about 77% of total participants
with follow-up data were 23.99% (95%
CI25.16 to22.83). For comparison, we
calculated weight change at 1 year and
3 years among the 1,503 (59% of those
enrolled) and 834 (33%) SDPI-DP partic-
ipants who completed 1 and 3 years of
follow-up, respectively, from baseline
data in Supplementary Table 1 and follow-
up data in Table 2 of the article by Jiang
et al. (10). The 1-year weight change
(pounds) was (212.0 2 215.5)/215.5 =
21.6%. The 3-year change was (215.1 2
212.6)/212.6 = +1.2%. Weight change
of this magnitude had no apparent effect
on the diabetes incidence rate in the life-
style intervention participants in the DPP
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(18). Weight loss and retention may have
been better had SDPI-DP provided more
intervention beyond the first 16 lifestyle
lessons. Many studies have shown that
short-term lifestyle interventions are in-
sufficient for assuring weight mainte-
nance (19). Indeed, long-range support
was central to the original DPP interven-
tion (17).
Key differences between RCTs and
implementation programs such as the
SDPI-DP are summarized in Table 1.
These two activities have different pri-
mary purposes (evaluating interventions
vs. providing service). Because RCTs in-
clude at least two interventions (one of
which may be placebo or standard care)
that are assigned randomly, they are
optimal for evaluating interventions of
unknown effect. By contrast, implemen-
tation programs provide service using
interventions with (presumed) known
benefits. RCTs provide internal validity,
but the ability to generalize their findings
is often unknown. Implementation pro-
grams may shed light on the effectiveness
of interventions in practice, although
their evaluation can be difficult, as illus-
trated by SDPI-DP.
In conclusion, through the SDPI-DP,
the Indian Health Service has continued
its admirable tradition of translating med-
ical research findings into practice in
challenging settings—often in isolated,
rural, and economically deprived areas.
The Indian Health Service has greatly im-
proved the quality of service for treating
diabetes and its complications since 1998
through the Special Diabetes Program for
Indians (20,21). This high level of service
is being extended to diabetes prevention,
although important challenges remain.
The SDPI-DP’s strongest contribution is
in showing that components of the DPP
core curriculum can be adapted for deliv-
ery to a large and diverse American Indian
population. Although the lack of a com-
parison group and high loss to follow-up
temper conclusions about its long-range
effectiveness, these findings should fuel
further exploration of how such programs
might be improved or integrated with
other preventive efforts to reach more in-
dividuals and engage them over longer
periods of time to prevent type 2 diabetes
and its complications.
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